Gene Polymorphism in Tinea Versicolor
Launched by KASR EL AINI HOSPITAL · Feb 21, 2021
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it.
- • Patients of both genders.
- • Age ≥18 years old.
- Exclusion Criteria:
- • - Patients with other cutaneous diseases.
- • Patient's having dandruff (scaly scalp) even if not symptomatizing.
- • Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects.
- • Patients with autoimmune diseases.
- • Patients with immunodeficiency diseases.
- • Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.
About Kasr El Aini Hospital
Kasr El Aini Hospital, a prestigious medical institution affiliated with Cairo University, is dedicated to advancing healthcare through innovative clinical research. With a commitment to excellence, the hospital serves as a leading sponsor of clinical trials, leveraging its state-of-the-art facilities and a multidisciplinary team of healthcare professionals. The institution focuses on a diverse range of therapeutic areas, aiming to improve patient outcomes and contribute to the global medical community. By fostering collaboration and adhering to the highest ethical standards, Kasr El Aini Hospital plays a pivotal role in the development of new treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, El Manial, Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials